CUENCA

Main information

  • Trade name:
  • CUENCA Film Coated Tablet 320 Milligram
  • Dosage:
  • 320 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CUENCA Film Coated Tablet 320 Milligram
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA1239/009/004
  • Authorization date:
  • 20-05-2011
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Cuenca320mgfilm-coatedtablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Onefilm-coatedtabletcontains320mgofvalsartan

Excipients

Eachtabletcontains

sorbitol37.0mg

lactose4.3mg

sodium1.28mg(0.06mmol)

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Film-coatedtablet.

Oblong,coated,scoredononeside,greyish-violetfilm-coatedtablets.

Thetabletcanbedividedintoequalhalves.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Hypertension

Treatmentofessentialhypertension.

4.2Posologyandmethodofadministration

Hypertension.

TherecommendedstartingdoseofCuencais80mgoncedaily.Theantihypertensiveeffectissubstantiallypresent

within2weeks,andmaximaleffectsareattainedwithin4weeks.Insomepatientswhosebloodpressureisnot

adequatelycontrolled,thedosecanbeincreasedto160mgandtoamaximumof320mg.

Cuencamayalsobeadministeredwithotherantihypertensiveagents.Theadditionofadiureticsuchas

hydrochlorothiazidewilldecreasebloodpressureevenfurtherinthesepatients.

Methodofadministration

Cuencamaybetakenindependentlyofamealandshouldbeadministeredwithwater.

Additionalinformationonspecialpopulations

Elderly

Nodoseadjustmentisrequiredinelderlypatients.

Renalimpairment

Nodosageadjustmentisrequiredforpatientswithacreatinineclearance>10ml/min(seesections4.4and5.2)

Hepaticimpairment

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 1

mg.Cuencaiscontraindicatedinpatientswithseverehepaticimpairmentandinpatientswithcholestasis(seesections

4.3,4.4and5.2).

Paediatricpatients

Cuencaisnotrecommendedforuseinchildrenbelowtheageof18yearsduetoalackofdataonsafetyandefficacy.

4.3Contraindications

-Hypersensitivitytotheactivesubstanceortoanyoftheexcipients.

-Severehepaticimpairment,biliarycirrhosisandcholestasis.

-Secondandthirdtrimesterofpregnancy(seesections4.4and4.6).

4.4Specialwarningsandprecautionsforuse

Hyperkalaemia

Concomitantusewithpotassiumsupplements,potassium-sparingdiuretics,saltsubstitutescontainingpotassium,or

otheragentsthatmayincreasepotassiumlevels(heparin,etc.)isnotrecommended.Monitoringofpotassiumshouldbe

undertakenasappropriate.

Sodium-and/orvolume-depletedpatients

Inseverelysodium-depletedand/orvolume-depletedpatients,suchasthosereceivinghighdosesofdiuretics,

symptomatichypotensionmayoccurinrarecasesafterinitiationoftherapywithCuenca.Sodiumand/orvolume

depletionshouldbecorrectedbeforestartingtreatmentwithCuenca,forexamplebyreducingthediureticdose.

Renalarterystenosis

Inpatientswithbilateralrenalarterystenosisorstenosistoasolitarykidney,thesafeuseofCuencahasnotbeen

established.

Short-termadministrationofCuencatotwelvepatientswithrenovascularhypertensionsecondarytounilateralrenal

arterystenosisdidnotinduceanysignificantchangesinrenalhaemodynamics,serumcreatinine,orbloodureanitrogen

(BUN).However,otheragentsthataffecttherenin-angiotensinsystemmayincreasebloodureaandserumcreatininein

patientswithunilateralrenalarterystenosis,thereforemonitoringofrenalfunctionisrecommendedwhenpatientsare

treatedwithvalsartan.

Kidneytransplantation

ThereiscurrentlynoexperienceonthesafeuseofCuencainpatientswhohaverecentlyundergonekidney

transplantation.

Primaryhyperaldosteronism

PatientswithprimaryhyperaldosteronismshouldnotbetreatedwithCuencaastheirrenin-angiotensinsystemisnot

activated.

Aorticandmitralvalvestenosis,obstructivehypertrophiccardiomyopathy

Aswithallothervasodilators,specialcautionisindicatedinpatientssufferingfromaorticormitralstenosis,or

hypertrophicobstructivecardiomyopathy(HOCM).

Impairedrenalfunction

Nodosageadjustmentisrequiredforpatientswithacreatinineclearance>10ml/min.Thereiscurrentlynoexperience

onthesafeuseinpatientswithacreatinineclearance<10ml/minandpatientsundergoingdialysis,thereforevalsartan

shouldbeusedwithcautioninthesepatients(seesections4.2and5.2).

Hepaticimpairment

Inpatientswithmildtomoderatehepaticimpairmentwithoutcholestasis,Cuencashouldbeusedwithcaution(see

sections4.2and5.2).

Pregnancy

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 2

therapyisconsideredessential,patientsplanningpregnancyshouldbechangedtoalternativeanti-hypertensive

treatmentswhichhaveanestablishedsafetyprofileforuseinpregnancy.Whenpregnancyisdiagnosed,treatmentwith

AIIRAsshouldbestoppedimmediately,and,ifappropriate,alternativetherapyshouldbestarted(seesections4.3and

4.6).

Otherconditionswithstimulationoftherenin-angiotensinsystem

Inpatientswhoserenalfunctionmaydependontheactivityoftherenin-angiotensinsystem(e.gpatientswithsevere

congestiveheartfailure),treatmentwithangiotensinconvertingenzymeinhibitorshasbeenassociatedwitholiguria

and/orprogressiveazotaemiaandinrarecaseswithacuterenalfailureand/ordeath.AsvalsartanisanangiotensinII

antagonist,itcannotbeexcludedthattheuseofCuencamaybeassociatedwithimpairmentoftherenalfunction.

Warningaboutexcipients:

Thismedicinecontainssorbitol.Patientswithhereditaryproblemsoffructoseintoleranceshouldnottakethis

medicine.

Thismedicinecontainslactose.Patientswithhereditaryproblemsofgalactoseintolerance,theLapplactasedeficiency

(insufficiencyobservedincertainpopulationsofLaponia)orglucose-galactosemalabsorptionshouldnottakethis

medicine.

Thismedicinecontainslessthan23mgofsodiumperdose;thatis,essentially“sodiumfree”.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Concomitantusenotrecommended

Lithium

ReversibleincreasesinserumlithiumconcentrationsandtoxicityhavebeenreportedduringconcurrentuseofACE

inhibitors.Duetothelackofexperiencewithconcomitantuseofvalsartanandlithium,thiscombinationisnot

recommended.Ifthecombinationprovesnecessary,carefulmonitoringofserumlithiumlevelsisrecommended.

Potassium-sparingdiuretics,potassiumsupplements,saltsubstitutescontainingpotassiumandothersubstancesthat

mayincreasepotassiumlevels

Ifamedicinalproductthataffectspotassiumlevelsisconsiderednecessaryincombinationwithvalsartan,monitoring

ofpotassiumplasmalevelsisadvised.

Cautionrequiredwithconcomitantuse

Non-steroidalanti-inflammatorymedicines(NSAIDs),includingselectiveCOX-2inhibitors,acetylsalicylicacid>3

g/day),andnon-selectiveNSAIDs

WhenangiotensinIIantagonistsareadministeredsimultaneouslywithNSAIDs,attenuationoftheantihypertensive

effectmayoccur.Furthermore,concomitantuseofangiotensinIIantagonistsandNSAIDsmayleadtoanincreased

riskofworseningofrenalfunctionandanincreaseinserumpotassium.Therefore,monitoringofrenalfunctionatthe

beginningofthetreatmentisrecommended,aswellasadequatehydrationofthepatient.

Others

Indruginteractionstudieswithvalsartan,nointeractionsofclinicalsignificancehavebeenfoundwithvalsartanorany

ofthefollowingsubstances:cimetidine,warfarin,furosemide,digoxin,atenolol,indometacin,hydrochlorothiazide,

amlodipine,glibenclamide.

4.6Fertility,pregnancyandlactation

Pregnancy:

EpidemiologicalevidenceregardingtheriskofteratogenicityfollowingexposuretoACEinhibitorsduringthefirst

trimesterofpregnancyhasnotbeenconclusive;however,asmallincreaseinriskcannotbeexcluded.Whilstthereis TheuseofAngiotensinIIReceptorAntagonists(AIIRAs)isnotrecommendedduringthefirst

trimesterofpregnancy(seesection4.4).TheuseofAIIRAsiscontra-indicatedduringthe

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 3

nocontrolledepidemiologicaldataontheriskwithAIIRAs,similarrisksmayexistforthisclassofdrugs.Unless

continuedAIIRAtherapyisconsideredessential,patientsplanningpregnancyshouldbechangedtoalternativeanti-

hypertensivetreatmentswhichhaveanestablishedsafetyprofileforuseinpregnancy.

Whenpregnancyisdiagnosed,treatmentwithAIIRAsshouldbestoppedimmediately,and,ifappropriate,alternative

therapyshouldbestarted.

AIIRAstherapyexposureduringthesecondandthirdtrimestersisknowntoinducehumanfetotoxicity(decreased

renalfunction,oligohydramnios,skullossificationretardation)andneonataltoxicity(renalfailure,hypotension,

hyperkalemia);seealsosection5.3“Preclinical

safetydata”.

ShouldexposuretoAIIRAshaveoccurredfromthesecondtrimesterofpregnancy,ultrasoundcheckofrenalfunction

andskullisrecommended.

InfantswhosemothershavetakenAIIRAsshouldbecloselyobservedforhypotension(seealsosections4.3and4.4).

Lactation

Becausenoinformationisavailableregardingtheuseofvalsartanduringbreastfeeding,Cuencaisnotrecommended

andalternativetreatmentswithbetterestablishedsafetyprofilesduringbreast-feedingarepreferable,especiallywhile

nursinganewbornorpreterminfant.

4.7Effectsonabilitytodriveandusemachines

Nostudiesontheeffectsontheabilitytodrivehavebeenperformed.Whendrivingvehiclesoroperatingmachinesit

shouldbetakenintoaccountthatoccasionallydizzinessorwearinessmayoccur.

4.8Undesirableeffects

Incontrolledclinicalstudiesinpatientswithhypertension,theoverallincidenceofadversereactions(ADRs)was

comparablewithplaceboandisconsistentwiththepharmacologyofvalsartan.TheincidenceofADRsdidnotappear

toberelatedtodoseortreatmentdurationandalsoshowednoassociationwithgender,ageorrace.

TheADRsreportedfromclinicalstudies,post-marketingexperienceandlaboratoryfindingsarelistedbelowaccording

tosystemorganclass.

Adversereactionsarerankedbyfrequency,themostfrequentfirst,usingthefollowingconvention:Verycommon

(1/10),

Common(1/100to<1/10)

Uncommon(1/1,000to<1/100)

Rare(1/10,000to<1/1,000)

Veryrare(<1/10,000)

Notknown(cannotbeestimatedfromtheavailabledata)

.Withineachfrequencygrouping,adversereactionsarerankedinorderofdecreasingseriousness.

ForalltheADRsreportedfrompost-marketingexperienceandlaboratoryfindings,itisnotpossibletoapplyanyADR

frequencyandthereforetheyarementionedwitha"notknown"frequency.

Hypertension

Bloodandlymphaticsystemdisorders

Notknown Decreaseinhaemoglobin,Decreasein

haematocrit,Neutropenia,Thrombocytopenia

Immunesystemdisorders

Notknown Hypersensitivityincludingserumsickness

Metabolismandnutritiondisorders

Notknown Increaseofserumpotassium

Earandlabyrinthsystemdisorders

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 4

Thesafetyprofileseenincontrolled-clinicalstudiesinpatientswithpost-myocardialinfarctionand/orheartfailure

variesfromtheoverallsafetyprofileseeninhypertensivepatients.Thismayrelatetothepatientsunderlyingdisease.

ADRsthatoccurredinpost-myocardialinfarctionand/orheartfailurepatientsarelistedbelow:

Vasculardisorders

Notknown Vasculitis

Respiratory,thoracicandmediastinaldisorders

Uncommon Cough

Gastrointestinaldisorders

Uncommon Abdominalpain

Hepato-biliarydisorders

Notknown Elevationofliverfunctionvaluesincluding

increaseofserumbilirubin

Skinandsubcutaneoustissuedisorders

Notknown Angioedema,Rash,Pruritus

Musculoskeletalandconnectivetissuedisorders

Notknown Myalgia

Renalandurinarydisorders

Notknown Renalfailureandimpairment,Elevationof

serumcreatinine

Generaldisordersandadministrationsiteconditions

Uncommon Fatigue

Bloodandlymphaticsystemdisorders

Notknow Thrombocytopenia

Immunesystemdisorders

Notknown Hypersensitivityincludingserumsickness

Metabolismandnutritiondisorders

Uncommon Hyperkalaemia

Notknown Increaseofserumpotassium

Nervoussystemdisorders

Common Dizziness,Posturaldizziness

Uncommon Syncope,Headache

Earandlabyrinthsystemdisorders

Uncommon Vertigo

Cardiacdisorders

Uncommon Cardiacfailure

Vasculardisorders

Common Hypotension,Orthostatichypotension

Notknown Vasculitis

Respiratory,thoracicandmediastinaldisorders

Uncommon Cough

Gastrointestinaldisorders

Uncommon Nausea,Diarrhoea

Hepato-biliarydisorders

Notknown Elevationofliverfunctionvalues

Skinandsubcutaneoustissuedisorders

Uncommon Angioedema

Notknown Rash,Pruritis

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 5

4.9Overdose

Symptoms

ACuencaoverdosecouldpossiblycauseamarkedhypotensionthatundercertaincircumstancescouldleadto

depressedlevelofconsciousness,circulatorycollapseand/orshock.

Therapy

Therapeuticmeasuresdependonwhenthemedicinewastaken,aswellasthetypeandseverityofthesymptoms.Here

restorationofstablecirculatoryconditionsshouldbethemainconcern.

Afteranoverdose,thepatientsshouldreceiveasufficientquantityofactivatedcharcoal.

Incaseofhypotensionthepatientshouldbeplacedinahorizontalposition.Saltandplasmareplacementpreparations

shouldberapidlyadministered.

Valsartancannotberemovedbyhaemodialysisduetoitsstrongplasma-proteinbonding.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:AngiotensinIIAntagonists,plain,ATCcode:C09CA03

Valsartanisanorallyactive,potent,andspecificangiotensinII(AngII)receptorantagonist.Itactsselectivelyonthe

AT1receptorsubtype,whichisresponsiblefortheknownactionsofangiotensinII.TheincreasedplasmalevelsofAng

IIfollowingAT1receptorblockadewithvalsartanmaystimulatetheunblockedAT2receptor,whichappearsto

counterbalancetheeffectoftheAT1receptor.ValsartandoesnotexhibitanypartialagonistactivityattheAT1

receptorandhasmuch(about20,000fold)greateraffinityfortheAT1receptorthanfortheAT2receptor.Valsartanis

notknowntobindtoorblockotherhormonereceptorsorionchannelsknowntobeimportantincardiovascular

regulation.

ValsartandoesnotinhibitACE(alsoknownaskininaseII)whichconvertsAngItoAngIIanddegradesbradykinin.

SincethereisnoeffectonACEandnopotentiationofbradykininorsubstanceP,angiotensinIIantagonistsare

unlikelytobeassociatedwithcoughing.InclinicaltrialswherevalsartanwascomparedwithanACEinhibitor,the

incidenceofdrycoughwassignificantly(P<0.05)lessinpatientstreatedwithvalsartanthaninthosetreatedwithan

ACEinhibitor(2.6%versus7.9%respectively).InaclinicaltrialofpatientswithahistoryofdrycoughduringACE

inhibitortherapy,19.5%oftrialsubjectsreceivingvalsartanand19.0%ofthosereceivingathiazidediuretic

experiencedcoughcomparedto68.5%ofthosetreatedwithanACEinhibitor(P<0.05).

Hypertension

AdministrationofCuencatopatientswithhypertensionresultsinreductionofbloodpressurewithoutaffectingpulse

rate.

Inmostpatients,afteradministrationofasingleoraldose,onsetofantihypertensiveactivityoccurswithin2hours,and

thepeakreductionofbloodpressureisachievedwithin4-6hours.Theantihypertensiveeffectpersistsover24hours

afterdosing.Duringrepeateddosing,theantihypertensiveeffectissubstantiallypresentwithin2weeks,andmaximal

Notknown Myalgia

Renalandurinarydisorders

Common Renalfailureandimpairment

Uncommon Acuterenalfailure,Elevationofserum

creatinine

Notknown IncreaseinBloodUreaNitrogen

Generaldisordersandadministrationsiteconditions

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 6

significantadditionalreductioninbloodpressureisachieved.

AbruptwithdrawalofCuencahasnotbeenassociatedwithreboundhypertensionorotheradverseclinicalevents.

Inhypertensivepatientswithtype2diabetesandmicroalbuminuria,valsartanhasbeenshowntoreducetheurinary

excretionofalbumin.TheMARVAL(MicroAlbuminuriaReductionwithValsartan)studyassessedthereductionin

urinaryalbuminexcretion(UAE)withvalsartan(80-160mg/od)versusamlodipine(5-10mg/od),in332type2

diabeticpatients(meanage:58years;265men)withmicroalbuminuria(valsartan:58µg/min;amlodipine:55.4

µg/min),normalorhighbloodpressureandwithpreservedrenalfunction(bloodcreatinine<120µmol/l).At24weeks,

UAEwasreduced(p<0.001)by42%(–24.2µg/min;95%CI:–40.4to–19.1)withvalsartanandapproximately3%(–

1.7µg/min;95%CI:–5.6to14.9)withamlodipinedespitesimilarratesofbloodpressurereductioninbothgroups.

TheCuencaReductionofProteinuria(DROP)studyfurtherexaminedtheefficacyofvalsartaninreducingUAEin391

hypertensivepatients(BP=150/88mmHg)withtype2diabetes,albuminuria(mean=102µg/min;20-700µg/min)and

preservedrenalfunction(meanserumcreatinine=80µmol/l).Patientswererandomizedtooneof3dosesofvalsartan

(160,320and640mg/od)andtreatedfor30weeks.Thepurposeofthestudywastodeterminetheoptimaldoseof

valsartanforreducingUAEinhypertensivepatientswithtype2diabetes.At30weeks,thepercentagechangeinUAE

wassignificantlyreducedby36%frombaselinewithvalsartan160mg(95%CI:22to47%),andby44%with

valsartan320mg(95%CI:31to54%).Itwasconcludedthat160-320mgofvalsartanproducedclinicallyrelevant

reductionsinUAEinhypertensivepatientswithtype2diabetes.

5.2Pharmacokineticproperties

Absorption:

Followingoraladministrationofvalsartanalone,peakplasmaconcentrationsofvalsartanarereachedin2–4hours.

Meanabsolutebioavailabilityis23%.Fooddecreasesexposure(asmeasuredbyAUC)tovalsartanbyabout40%and

peakplasmaconcentration(Cmax)byabout50%,althoughfromabout8hpostdosingplasmavalsartanconcentrations

aresimilarforthefedandfastedgroups.ThisreductioninAUCisnot,however,accompaniedbyaclinically

significantreductioninthetherapeuticeffect,andvalsartancanthereforebegiveneitherwithorwithoutfood.

Distribution:

Thesteady-statevolumeofdistributionofvalsartanafterintravenousadministrationisabout17litres,indicatingthat

valsartandoesnotdistributeintotissuesextensively.Valsartanishighlyboundtoserumproteins(94–97%),mainly

serumalbumin.

Biotransformation:

Valsartanisnotbiotransformedtoahighextentasonlyabout20%ofdoseisrecoveredasmetabolites.Ahydroxy

metabolitehasbeenidentifiedinplasmaatlowconcentrations(lessthan10%ofthevalsartanAUC).Thismetaboliteis

pharmacologicallyinactive.

Excretion:

Valsartanshowsmultiexponentialdecaykinetics(t½<1handt½ßabout9h).Valsartanisprimarilyeliminatedby

biliaryexcretioninfaeces(about83%ofdose)andrenallyinurine(about13%ofdose),mainlyasunchangeddrug.

Followingintravenousadministration,plasmaclearanceofvalsartanisabout2l/handitsrenalclearanceis0.62l/h

(about30%oftotalclearance).Thehalf-lifeofvalsartanis6hours.

Specialpopulations

Elderly

Asomewhathighersystemicexposuretovalsartanwasobservedinsomeelderlysubjectsthaninyoungsubjects;

however,thishasnotbeenshowntohaveanyclinicalsignificance.

Impairedrenalfunction

Asexpectedforacompoundwhererenalclearanceaccountsforonly30%oftotalplasmaclearance,nocorrelationwas

seenbetweenrenalfunctionandsystemicexposuretovalsartan.Doseadjustmentisthereforenotrequiredinpatients

withrenalimpairment(creatinineclearance>10ml/min).Thereiscurrentlynoexperienceonthesafeuseinpatients

withacreatinineclearance<10ml/minandpatientsundergoingdialysis,thereforevalsartanshouldbeusedwith

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 7

removedbydialysis.

Hepaticimpairment

Approximately70%ofthedoseabsorbediseliminatedinthebile,essentiallyintheunchangedform.Valsartandoes

notundergoanynoteworthybiotransformation.Adoublingofexposure(AUC)wasobservedinpatientswithmildto

moderatehepaticimpairmentcomparedtohealthysubjects.However,nocorrelationwasobservedbetweenplasma

valsartanconcentrationversusdegreeofhepaticdysfunction.Cuencahasnotbeenstudiedinpatientswithsevere

hepaticdysfunction(seesections4.2,4.3and4.4).

5.3Preclinicalsafetydata

Non-clinicaldatarevealnospecialhazardforhumansbasedonconventionalstudiesofsafetypharmacology,repeated

dosetoxicity,genotoxicity,carcinogenicpotential.

Inrats,maternallytoxicdoses(600mg/kg/day)duringthelastdaysofgestationandlactationledtolowersurvival,

lowerweightgainanddelayeddevelopment(pinnadetachmentandear-canalopening)intheoffspring(seesection

4.6).Thesedosesinrats(600mg/kg/day)areapproximately18timesthemaximumrecommendedhumandoseona

mg/m2basis(calculationsassumeanoraldoseof320mg/dayanda60-kgpatient).

Innon-clinicalsafetystudies,highdosesofvalsartan(200to600mg/kgbodyweight)causedinratsareductionofred

bloodcellparameters(erythrocytes,haemoglobin,haematocrit)andevidenceofchangesinrenalhaemodynamics

(slightlyraisedplasmaurea,andrenaltubularhyperplasiaandbasophiliainmales).Thesedosesinrats(200and600

mg/kg/day)areapproximately6and18timesthemaximumrecommendedhumandoseonamg/m2basis(calculations

assumeanoraldoseof320mg/dayanda60-kgpatient).

Inmarmosetsatsimilardoses,thechangesweresimilarthoughmoresevere,particularlyinthekidneywherethe

changesdevelopedtoanephropathywhichincludedraisedureaandcreatinine.

Hypertrophyoftherenaljuxtaglomerularcellswasalsoseeninbothspecies.Allchangeswereconsideredtobecaused

bythepharmacologicalactionofvalsartanwhichproducesprolongedhypotension,particularlyinmarmosets.For

therapeuticdosesofvalsartaninhumans,thehypertrophyoftherenaljuxtaglomerularcellsdoesnotseemtohaveany

relevance.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Tabletcore

Cellulose,microcrystalline(E460)

Silica,colloidalanhydrous(E551)

Sorbitol(E-420)

Magnesiumcarbonate(E504)

Maizestarch,pregelatinised

PovidoneK-25(E1201)

Sodiumstearylfumarate

Sodiumlaurylsulphate

CrospovidoneTypeA(E1202)

Filmcoating

Lactosemonohydrate

Hypromellose(E464)

Titaniumdioxide(E171)

Macrogol

Yellowironoxide(E172)

Brownironoxide(E712)

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 8

6.2Incompatibilities

Notapplicable

6.3Shelflife

1year

6.4Specialprecautionsforstorage

Donotstoreabove30°C.Storeintheoriginalpackageinordertoprotectfrommoisture.

6.5Natureandcontentsofcontainer

PVC/PE/PVDC/aluminiumblister.

Packsizes:7,14,28,56,98,280film-coatedtablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposalandotherhandling

Nospecialrequirements.

Anyunusedproductorwasteshouldbedisposedofinaccordancewithlocalrequirements.

7MARKETINGAUTHORISATIONHOLDER

LaboratoriosLiconsa,S.A.

GranVíaCarlosIII,98,7thfloor

08028Barcelona,SPAIN

8MARKETINGAUTHORISATIONNUMBER

PA1239/9/4

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:20 th

May2011

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/05/2011 CRN 2058537 page number: 9